COMS receives award
Previous Venture of the Year award winners include Orthohelix Surgical Designs (2013), Cleveland Heart Lab (2012), Turning Technologies (2011), PartsSource (2010) and Brulant, which later merged into Rosetta (2009). Other finalists for the OVA 2014 award were Juventas Therapeutics and nChannel, Inc.
COMS original investors included Carleton McKenna & Co., Next Sparc, and Zapis Capital. The company also secured $21 million of growth and recapitalization capital from Summit, an increase in staff and further penetration into adjacent markets.
“As an independent investment banking firm, we work with and develop growth capital strategies for organizations throughout the country,” noted Paul H. Carleton, managing partner at Carleton McKenna & Co. “COMS is a rare combination of clinical, technical and business aptitude yielding impressive results, making it an excellent choice for the OVA Venture of the Year Award.”